XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?
Yahoo Finance
Read Full Article at Yahoo Finance →Ad Slot — In-Article (728x90)
PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half the volatility.
This is a summary. For the full story, read the original article at Yahoo Finance.
Original source: Yahoo Finance